Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in Chinese patients with adenomyosis

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000039040

Enrollment

Unknown

Registered

2020-10-14

Start date

2020-11-01

Completion date

Unknown

Last updated

2021-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

adenomyosis

Interventions

experimental group:Dienogest

Eligibility

Sex/Gender

Female

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 20 years or older; 2. regular menstrual cycles of 38 days or less; 3. adenomyosis diagnosed by imaging analysis (both magnetic resonance imaging [MRI] and transvaginal sonography); 4. pain symptoms (lower abdominal pain and/or lumbago) scoring three points or more on the verbal pain rating scale during the menstrual cycle.

Exclusion criteria

Exclusion criteria: 1.Endometriosis or uterine leiomyoma diagnosed by imaging analysis (both MRI and transvaginal sonography); 2.Severe anemia (hemoglobin concentrations 10cm or myometrial thickness, > 4cm).

Design outcomes

Primary

Measure	Time frame
pain;	—

Secondary

Measure	Time frame
size of uterus;size of ovary cyst;Bleeding patterns;hemoglobin;CA125;BMI;Kupperman score;E2;FSH;LH;Liver and kidney function index;BMD (bone mineral density);	—

Countries

China

Contacts

Public ContactLijie Wang

Department of Obstetrics and Gynecology, Qilu hospital, Shandong University, Jinan, China

wangljie@hotmail.com+86 18560081857

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026